News

Research – electroCore (ECOR) – Q3 2019: Revising Outlook After Slow Quarter

Health
0 min read

Friday, November 15, 2019

electroCore (ECOR)

Q3 2019: Revising Outlook After Slow Quarter

electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Third quarter 2019 financial results. The company reported net sales of $683,000 compared to $623,000 and $410,000, respectively, in the two previous quarters of 2019. Forty and 25 percent of the total sales in the quarter were attributed to the federal supply schedule (FSS)and the United Kingdom (UK) channels,respectively. No additional payers or lives were added/disclosed to the current reimbursement coverage.
  • Did the results meet expectations?  We believe the recent numbers do not demonstrate the expected revenue ramp-up. In the quarter, we did not see the near-term positive trajectory in…



    Get full report on Channelchek desktop.


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.